Advertisement
Advertisement
CGON
CG Oncology, Inc. Common stock
72.64
USDSponsored
-2.10
-2.81%
Nov 10, 15:59 UTC -5
Closed
After-Market
72.66
+0.02
+0.02%
CG Oncology, Inc. Common stock (CGON) Earnings
CGON Earnings Reports
Positive Surprise Ratio
CGON beat 5 of 12 last estimates.
42%
Next Report
Date of Next Report
Feb 25, 2027
Estimate for Q4 26 (Revenue/ EPS)
$579.70K
/-$0.83
Implied change from Q3 26 (Revenue/ EPS)
-63.86%
/+29.69%
Implied change from Q4 25 (Revenue/ EPS)
-75.03%
/+56.60%
CG Oncology, Inc. Common stock earnings per share and revenue
On Nov 06, 2026, CGON reported earnings of -0.64 USD per share (EPS) for Q3 26, beating the estimate of -0.85 USD, resulting in a 25.37% surprise. Revenue reached 1.60 million, compared to an expected 492.15 thousand, with a 225.92% difference. The market reacted with a +17.27% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of -0.83 USD, with revenue projected to reach 579.70 thousand USD, implying an increase of 29.69% EPS, and decrease of -63.86% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Scholar Rock Holding Corporation Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.86
Actual
-$0.81
Surprise
+6.18%
Legend Biotech Corporation - ADR
Report Date
Nov 10, 2026 For Q3 26
Estimate
$0.00
Actual
$0.13
Surprise
+9,900.00%
Hemab Therapeutics Holdings, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.53
Actual
-$0.57
Surprise
-8.51%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.63
Actual
-$0.73
Surprise
-14.53%
Opus Genetics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.15
Actual
-$0.18
Surprise
-19.68%
Protalix BioTherapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.03
Actual
$0.05
Surprise
+265.02%
PepGen Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.19%
MaxCyte, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.07
Actual
-$0.05
Surprise
+36.79%
Humacyte, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.07
Surprise
+22.91%
Atossa Therapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.90
Actual
-$0.56
Surprise
+38.31%
FAQ
What were CG Oncology, Inc. Common stock's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, CG Oncology, Inc. Common stock reported EPS of -$0.64, beating estimates by 25.37%, and revenue of $1.60M, 225.92% above expectations.
How did the market react to CG Oncology, Inc. Common stock's Q3 2026 earnings?
The stock price moved up 17.27%, changed from $64.80 before the earnings release to $75.99 the day after.
When is CG Oncology, Inc. Common stock expected to report next?
The next earning report is scheduled for Feb 25, 2027.
What are the forecasts for CG Oncology, Inc. Common stock's next earnings report?
Based on --
analysts, CG Oncology, Inc. Common stock is expected to report EPS of -$0.83 and revenue of $579.70K for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.